Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (RNAC): 5 pipeline candidates · 2 upcoming catalysts · ~16 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.4 months
D/E -2.95 · 0% dilution
Lead: Phase 3
5 candidates
2 upcoming, next in ~12d
0 buys · 3 sells (180d)
A transparent, data-derived signal for Cartesian Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$303.1M
Cash
$120.4M
Quarterly Burn
$22.1M
Runway
16.4 mo
Revenue
$78K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| decartes-08 | Phase 3 |
| descartes-08 | Phase 3 |
| descartes-11 | Phase 3 |
| descartes-15 | Phase 3 |
| fludarabine | Phase 1 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
81
Total value held
$31.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 815,194 | $5.0M |
| fmr llc | 799,743 | $4.9M |
| blackrock, inc. | 599,108 | $3.7M |
| 683 capital management, llc | 330,000 | $2.0M |
| millennium management llc | 284,317 | $1.7M |
| geode capital management, llc | 263,694 | $1.6M |
| marshall wace, llp | 251,115 | $1.5M |
| state street corp | 200,337 | $1.2M |
| privium fund management b.v. | 179,114 | $1.1M |
| two sigma investments, lp | 167,313 | $1.0M |
Showing top 10 of 81 institutional holders of Cartesian Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cartesian Therapeutics, Inc.'s pipeline?
Cartesian Therapeutics, Inc. (RNAC) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cartesian Therapeutics, Inc.'s lead drug candidate?
Cartesian Therapeutics, Inc.'s most advanced tracked candidate is decartes-08 (Phase 3) for Myasthaenia Gravis.
What is Cartesian Therapeutics, Inc.'s next catalyst?
Cartesian Therapeutics, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of" — expected June 30, 2026.
What is Cartesian Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cartesian Therapeutics, Inc. has approximately 16.4 months of cash runway.
What is Cartesian Therapeutics, Inc.'s market capitalization?
Cartesian Therapeutics, Inc.'s market capitalization is approximately $303.1M.
Get the full picture on Cartesian Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.